Ricevi le ultime notizie sulle azioni ABVC BioPharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ABVC

Ultime notizie per

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

ABVC BioPharma Inc

Press Releases

ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

Health Care

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

General

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Apollomics Inc. - Class A Ordinary Shares

Apollomics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cue Biopharma

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immunic

MiNK Therapeutics

IO Biotech

Jasper Therapeutics, Inc. - Class A Common Stock

Comments

ABVC BioPharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO